← Back to Search

Other

LY3556050 for Diabetic Neuropathy

Phase 2
Waitlist Available
Research Sponsored by Eli Lilly and Company
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week 8
Awards & highlights

Study Summary

This study is evaluating whether a drug may help treat diabetic peripheral neuropathic pain.

Eligible Conditions
  • Diabetic Neuropathy

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 8
This trial's timeline: 3 weeks for screening, Varies for treatment, and week 8 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change From Baseline in Average Pain Intensity as Measured by the Numeric Rating Scale (NRS)
Secondary outcome measures
Change From Baseline for Overall Improvement as Measured by Patient's Global Impression of Change
Change From Baseline for Worst Pain Intensity as Measured by NRS
Change From Baseline in the Brief Pain Inventory-Short Form Modified (BPI-SFM) Total Pain Interference Score
+4 more

Side effects data

From 2021 Phase 2 trial • 202 Patients • NCT04627038
21%
Constipation
19%
Nausea
16%
Dizziness
14%
Fatigue
10%
Diarrhoea
6%
Abdominal pain upper
6%
Headache
5%
Abdominal discomfort
5%
Lethargy
4%
Dyspepsia
4%
Arthralgia
100%
80%
60%
40%
20%
0%
Study treatment Arm
LY3556050 600 mg
Placebo

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: 600 Milligram (mg) LY3556050Experimental Treatment1 Intervention
Participants received 600 mg LY3556050 twice daily (BID) every 12 hours for up to 8 weeks.
Group II: PlaceboPlacebo Group1 Intervention
Participants received placebo BID every 12 hours for up to 8 weeks.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
LY3556050
2021
Completed Phase 2
~520

Find a Location

Who is running the clinical trial?

Eli Lilly and CompanyLead Sponsor
2,618 Previous Clinical Trials
3,201,492 Total Patients Enrolled
Study DirectorEli Lilly and Company
1,347 Previous Clinical Trials
405,686 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who else is applying?

What state do they live in?
Florida
Pennsylvania
How old are they?
18 - 65
What site did they apply to?
Clinical Research Center of Reading,LLC
What portion of applicants met pre-screening criteria?
Met criteria
Did not meet criteria
Recent research and studies
clinicaltrials.govStudy
Chronic Pain Master Protocol (CPMP): A Study of LY3556050 in Participants With Diabetic Peripheral Neuropathic Pain
2021. "Chronic Pain Master Protocol (CPMP): A Study of LY3556050 in Participants With Diabetic Peripheral Neuropathic Pain". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04707157.
~17 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top